Any SP increases from Mt Cattlin will have to come from value added activities which improve the bottom line e.g.
- increased sales,
- lowered debt,
- lower costs of production,
- increased production output,
- higher Li concentrate pricing etc.
The value of the Mt Cattlin side of the business will come down to how much cold hard cash it can generate to fund SDV and James Bay. Financial metrics will be hugely important from now on.
The worst thing that could happen right now is a cost blow out, or delays in producing the product.
As for SDV and James Bay - we'll have to see how quickly the supply/demand gap for LCE narrows to see whether this has any accretive value to the SP.
- Forums
- ASX - By Stock
- GXY
- 3 dollars by 2018
3 dollars by 2018, page-156
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online